-
AbCellera Biologics (ABCL) PT Lowered to $49 at BMO Capital, Following Earnings
-
Pay More Attention to AbCellera Biologics (ABCL) on String of Positive News, BMO Says; Analyst Sees ~150% Upside
-
Pre-Open Stock Movers 09/17: (CRVS) (ABCL) (BGNE) Higher; (PTGX) (GRTS) (X) Lower (more...)
-
AbCellera Biologics (ABCL) PT Raised to $61 at BMO Capital
-
UPDATE: BMO Capital Starts AbCellera Biologics (ABCL) at Outperform
-
AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
-
AbCellera Biologics (ABCL) IPO Opens 205% Higher
-
AbCellera Biologics Inc. (ABCL) Prices 24.150M Share IPO at $20/Sh
-
AbCellera Announces Pricing of Initial Public Offering

